应用沃森肿瘤解决方案评价胃癌术后辅助治疗获益的研究

Evaluations of benefits of postoperative adjuvant therapy for gastric cancer by using artificial intelligent diagnosis and treatment system

应用IBM沃森肿瘤解决方案(WfO)评价既往胃癌术后辅助治疗的获益。在1390例胃癌住院人次中按纳入排除标准共筛选出46例胃癌术后辅助治疗患者并回访无病生存时间,同时将术前病历资料上传WfO,比对患者的实际术后治疗方案与沃森建议方案的一致性,分析一致组和非一致组之间的无病生存时间的统计学差异。入组患者中共有21(45.65%)例患者临床治疗方案与WfO推荐方案一致;一致组的无病生存时间(39.68月)明显高于非一致组(23.09月)(P=0.003)。沃森肿瘤解决方案推荐的治疗方案可以明显延长患者的无病生存时间,可为胃癌术后辅助治疗的规范化提供帮助。

To use IBM′s Watson for Oncology(WfO)to evaluate the benefits of postoperative adjuvant therapy for gastric cancer.46 cases of postoperative gastric cancer patients were enrolled by the inclusion and exclusion criteria in about 1 390 patients with gastric cancer in Anhui Provincial Hospital and disease-free survival was followed-up.The preoperative medical records were uploaded to WfO and the practical postoperative therapies were compared with Watson′s suggested solutions.A total of 21(45.65%)patients in the study group had the same clinical treatment plans as recommendations by WfO.The disease-free survival time of the consistent group(39.68 months)was significantly higher than that of the non-consistent group(23.09 months)(P=0.003).The treatment recommended by WfO could significantly prolong the patient′s disease-free survival and be conducive to the standardization of postoperative adjuvant therapy for gastric cancer.